On October 30, 2025, FUJIFILM Corporation made a strategic announcement to expand its NURA health screening center network across Southeast Asia, focusing on improving early detection of cancer and lifestyle-related diseases. The initiative aims to address health system gaps in preventive screening and diagnostics, empowering hospitals and healthcare providers in Vietnam, Thailand, the Philippines, and Malaysia. The Vietnamese location in Ho Chi Minh City is the first of the four new facilities to open, following the Hanoi NURA center launched in July 2024. Subsequent centers in Bangkok, Manila, and Kuala Lumpur will begin operations during fiscal year 2025, with direct management under Fujifilm in each country except Vietnam, where VIETNAM JAPAN HEALTH TECHNOLOGY JOINT STOCK COMPANY (VJH) continues operations in collaboration with local hospital infrastructure.

The deployment of these centers is a direct response to the rising burden of non-communicable diseases (NCDs) in the ASEAN region. According to public health data cited in Fujifilm’s release, about 9.5 million annual deaths in the region are caused by NCDs such as cancer, ischemic heart disease, and diabetes, with these diseases accounting for over half (55%) of total mortality rates. Alarmingly, nearly half those deaths occur in individuals under the age of 70, highlighting the importance of early intervention and routine screening as an operational imperative for healthcare providers.

Each NURA center is outfitted with high-throughput Fujifilm imaging solutions, including advanced CT scanners and mammography systems, as well as a comprehensive medical IT platform that leverages artificial intelligence for screening interpretation. The core proposition is operational efficiency; patients can complete screening panels and receive physician-reviewed results, including direct consultation over imaging, within approximately 120 minutes. The AI-assisted workflow is designed not only to improve diagnostic accuracy for cancer and NCDs but also to shorten patient turnaround—a critical factor for overburdened health systems and hospital administrators focused on throughput and quality outcomes.

From a facilities and workflow management perspective, this expansion holds significance for hospitals, private diagnostics networks, and clinical service providers across ASEAN. First, it increases market access to screening devices and cloud-enabled health IT systems, positioning local hospitals to enhance their preventive health service lines. Second, it provides a best-practice reference model for integrating AI into daily diagnostic routines, which can be applied or adapted by other providers in the network. Third, collaboration with local hospital operators—exemplified in Vietnam—facilitates capacity-building and knowledge transfer, benefiting regional workforce training and establishing new referral and partnership channels between domestic and multinational healthcare entities.

The move is consistent with Fujifilm’s global growth strategy in healthcare solutions, following successful NURA launches in India, Mongolia, Vietnam, and the UAE. The company has also outlined plans for expansion into other emerging markets, including new centers in South Africa and further ASEAN locations within the current fiscal year. This aligns with stakeholders’ increasing focus on digital transformation, diagnostic efficiency, and cross-border medical innovation as pillars of hospital business strategy in Asia.

For healthcare administrators, procurement professionals, and hospital clinical leadership, the expanded presence of the NURA facilities represents both a competitive challenge and a partnership opportunity. Procurement teams will note the impact on sourcing advanced imaging systems and interoperability with existing IT architecture, while facility managers and HIT leads can leverage the NURA operating model to benchmark patient throughput, AI deployment, and diagnostic reporting efficiencies. The strategic intent is clear: by reducing barriers to high-quality, rapid screening, the initiative aims to enhance healthcare delivery, improve population health metrics, and further anchor Fujifilm as a B2B technology and infrastructure partner for Asian hospital networks.